News

Pharmatek has acquired a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture. The technology can be used for both oral and parenteral dosage

TBDxV provides automated computer-aided analysis for a clinician; specifically displaying acid-fast tuberculosis (TB) bacteria using Signature Mapping’s advanced computer vision and pattern recognition technologies. Signature Mapping TBDxV software

The drugs are being distributed by American Regent subsidiary and Animal Health Division. The company’s decision follows the US food and Drug Administration’s (FDA) inspection and its meeting

CNV2197944 is a small molecule, state-dependent calcium channel blocker, intended to selectively inhibit highly active Cav2.2 channels. In preclinical studies, CNV2197944 has demonstrated safety and efficacy profile. Convergence

Jointly discovered by scientists at Sequella and the National Institute of Allergy and Infectious Diseases (NIAID), SQ109 is currently being investigated in Phase 2 efficacy studies in TB

While MSD brings the scientific excellence of the compound to the partnership, Sun Pharma brings its expertise in the marketing of drugs in the relevant therapeutic areas across

Depakote delayed-release tablets falls under the central nervous system (CNS) therapeutic category as a treatment for the manic episodes associated with bipolar disorder. They are indicated as monotherapy

Mircera Injection Syringe uses epoetin beta (genetical recombination) which is chemically combined with a single molecule of linear methoxy polyethylene glycol (PEG). It has a longer serum half-life

The increase was driven primarily by the continued growth of Tysabri (natalizumab) revenues, which increased 15% to $251m, and Avonex (interferon beta-1a) revenues, which increased 8% to $642m.